Literature DB >> 15736194

Interspecies scaling of biliary excreted drugs: a comparison of several methods.

Iftekhar Mahmood1.   

Abstract

The objective of this study was to evaluate the predictive performance of several methods of interspecies scaling for the prediction of human clearance of drugs which are excreted in the bile. Ten methods of allometric scaling were used to predict human clearance of biliary excreted drugs from animal data. The methods included the simple allometric approach; the rule of exponents; the rule of exponents with a correction factor; the ratio of human and monkey liver blood flow x monkey clearance; product of clearance and bile flow; product of clearance and UDGPT; product of clearance, bile flow, and UDGPT; and a modified version of the last three approaches in association with the rule of exponents. The results of the study indicate that among these ten approaches, the rule of exponents with the correction factor is the best approach for the prediction of human clearance for drugs which are excreted in the bile. The worst approach is the product of clearance, bile flow, and UDGPT. The simple allometry and the monkey liver blood flow (MLBF) approaches gave almost similar results. For some drugs the simple allometry predicted clearance better than the MLBF approach and vice versa. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15736194     DOI: 10.1002/jps.20313

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

Authors:  Venkata V Pavan Kumar; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

3.  A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Authors:  Thorsten Lehr; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Hans-Guenter Schaefer; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.

Authors:  An Van den Bergh; Vikash Sinha; Ron Gilissen; Roel Straetemans; Koen Wuyts; Denise Morrison; Luc Bijnens; Claire Mackie
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

Review 5.  Scaling and systems biology for integrating multiple organs-on-a-chip.

Authors:  John P Wikswo; Erica L Curtis; Zachary E Eagleton; Brian C Evans; Ayeeshik Kole; Lucas H Hofmeister; William J Matloff
Journal:  Lab Chip       Date:  2013-09-21       Impact factor: 6.799

6.  Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.

Authors:  Zvi Teitelbaum; Thierry Lave; Jan Freijer; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

7.  Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.

Authors:  Venkata V Pavankuamr; C A Vinu; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

8.  Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.

Authors:  Zhenhua Huang; Heran Li; Qian Zhang; Xiaojuan Tan; Fangzheng Lu; Hongzhuo Liu; Sanming Li
Journal:  Drug Des Devel Ther       Date:  2015-08-05       Impact factor: 4.162

9.  Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor.

Authors:  Ramesh Mullangi; Preeti Ahlawat; Ravi K Trivedi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

10.  Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.

Authors:  P Gardiner; C Wikell; S Clifton; J Shearer; A Benjamin; S A Peters
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.